The use of GLP-1 receptor agonists such as liraglutide and semaglutide has increased rapidly in recent years, particularly among women of reproductive age. These medications are widely prescribed for type 2 diabetes and, more recently, for weight management. As their popularity grows, so does concern about what happens when exposure occurs around the time of conception.
A newly published nationwide cohort study from Denmark provides important insights into this question. This article breaks down the findings in a clear, SEO-optimized format, helping patients, clinicians, and readers understand the potential risks and what they may mean in real-world settings.
GLP-1 receptor agonists are a class of medications that mimic a natural hormone involved in blood sugar regulation and appetite control. Drugs like liraglutide and semaglutide are commonly used to:
Because these medications can significantly affect metabolism and body weight, they are often used by women who may later plan pregnancy. However, they are not approved for use during pregnancy, and guidelines recommend avoiding them before conception.
Unplanned exposure to GLP-1 medications around conception is not uncommon. Until now, evidence on how such exposure affects pregnancy outcomes has been limited and sometimes conflicting.
This Danish nationwide study aimed to address that gap by analyzing over 750,000 pregnancies between 2009 and 2023. Among these, 529 pregnancies involved exposure to GLP-1 receptor agonists during the periconceptional period, defined as eight weeks before or after the last menstrual period.
The study initially observed higher rates of several complications among women exposed to GLP-1 medications. These included:
However, after adjusting for important factors such as maternal age, body mass index, smoking, and pre-existing diabetes, most of these associations disappeared.
The only outcome that remained significantly increased was the risk of preterm birth.
But there is an important nuance.
When researchers separated women based on why they were using GLP-1 medications, the results became much clearer.
Among women with pre-existing diabetes, the risk of preterm birth was higher when exposed to GLP-1 receptor agonists.
Among women without diabetes who were using these medications for weight loss, there was no increased risk of preterm birth.
This suggests that the underlying condition, diabetes, may be the primary driver of risk rather than the medication itself.
Preterm birth is already a known complication in pregnancies affected by diabetes. Poor glycemic control and metabolic factors can contribute to early delivery.
The study findings support the idea that:
This distinction is crucial for healthcare providers when counseling patients who may have been exposed to these medications unintentionally.
This research stands out for several reasons:
These features strengthen confidence in the findings.
Despite its strengths, the study has some limitations:
These factors mean the results should be interpreted with caution.
The study highlights several important considerations:
Women using GLP-1 medications should discuss pregnancy plans with their healthcare provider.
For women with diabetes, optimizing blood sugar control before conception remains critical.
Although GLP-1 drugs are effective for weight loss, they should not be used during pregnancy and should be discontinued in advance.
For women without diabetes who become pregnant while using these medications, the findings may provide some reassurance that risk is not increased.
Previous studies have shown mixed results. Some reported increased risks of complications, while others suggested protective effects.
This study adds clarity by demonstrating that:
It reinforces the need to look beyond medication exposure alone and consider the broader clinical context.
More research is needed to fully understand the safety of GLP-1 receptor agonists around pregnancy. Key areas include:
Such data will help refine clinical guidelines and improve patient care.
This large Danish cohort study provides valuable evidence on the relationship between GLP-1 receptor agonist exposure and pregnancy outcomes.
The key takeaway is that increased risk of preterm birth appears to be linked to diabetes rather than the medication itself. For women using these drugs for weight management, no increased risk was observed.
As the use of GLP-1 medications continues to grow, understanding their role in reproductive health will remain an important area of research and clinical practice.
Hviid KVR et al. (2026). Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. Human Reproduction Open, Volume 2026, Issue 2.
This article is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional regarding medications, pregnancy planning, or any health-related decisions. The findings summarized here are based on observational research and should not be interpreted as proof of cause and effect.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.